The <scp>NRF</scp>2 pathway as potential biomarker for dimethyl fumarate treatment in multiple sclerosis

Abstract

We demonstrate that positive effects of DMF on the clinical outcome are paralleled by induction of the antioxidant NRF2 transcriptional pathway and a shift toward regulatory immune cell subsets in the periphery. Our data identify a role of the NRF2 pathway as potential biomarker for DMF treatment in MS.